Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – HC Wainwright decreased their FY2025 EPS estimates for shares of Merus Labs International in a report issued on Thursday, March 27th. HC Wainwright analyst A. He now anticipates that the specialty pharmaceutical company will earn ($0.19) per share for the year, down from their previous forecast of ($0.18). HC Wainwright also issued estimates for Merus Labs International’s FY2026 earnings at ($0.22) EPS, FY2027 earnings at ($0.23) EPS and FY2028 earnings at ($0.22) EPS.
Merus Labs International Stock Performance
The business’s 50-day moving average is C$1.65. Merus Labs International has a 1 year low of C$0.95 and a 1 year high of C$1.76.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Recommended Stories
- Five stocks we like better than Merus Labs International
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- MarketBeat Week in Review – 03/24 – 03/28
- How to Profit From Growth Investing
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
